Vascular access site complications after PCI: Current status and future directions

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 8, 2006, Pages 402-403

  Hamon, Martial ^a  

^a CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; THROMBIN INHIBITOR;

ACUTE CORONARY SYNDROME; ANTICOAGULATION; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTINUING EDUCATION; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE ASSOCIATION; DRUG COST; ECONOMIC EVALUATION; FOLLOW UP; HEALTH CARE COST; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; INJECTION SITE BLEEDING; LENGTH OF STAY; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; RISK REDUCTION; ST SEGMENT ELEVATION; SURGICAL APPROACH; SYSTEMATIC REVIEW; THROMBOSIS; VASCULAR ACCESS;

ANGIOPLASTY, BALLOON, CORONARY; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; COMBINED MODALITY THERAPY; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; FEMORAL ARTERY; FIBRINOLYTIC AGENTS; HUMANS; INTRAOPERATIVE COMPLICATIONS; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 33746637929     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0607     Document Type: Review

References (11)

1. Rothman MT (2005) Drug insight: Bleeding after percutaneous coronary intervention-risks, measures and impact of anticoagulant treatment options. Nat Clin Pract Cardiovasc Med 2: 465-474
2. Kinnaird T et al. (2003) Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous interventions. Am J Cardiol 92: 930-935
3. Agostoni P et al. (2004) Radial versus femoral approach for percutaneous coronary diagnostic and interventional procedures. Systematic overview and meta-analysis of randomized trials. J Am Coll Cardiol 44: 349-356
4. Yusuf S et al. (2006) Comparison of Fondaparinux and Enoxaparin in Acute Coronary Syndromes. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. N Engl J Med 354: 1464-1476
5. Montalescot G (2005) STEEPLE: Safety and Efficacy of Ecnoxaparin in Percutaneous Coronary Interventin Patients, an International Randomised Evaluation. Presented at the European Society of Cardiology Congress: 2005, September 3-7; Stockholm, Sweden
6. Direct thrombin Inhibitor Trialists' Collaborative Group (2002) Direct Thrombin inhibitors in acute coronary syndromes: Principal results of a meta-analysis based on individual patients' data. Lancet 359: 294-302
7. Lincoff AM et al. (2003) Bivalirudin and provisional glycoprotein IIb/ IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention. REPLACE-2 randomized trial. JAMA 289: 853-863
8. Stone GW (2006) Prospective, randomized comparison of heparin plus IIb/ IIIa inhibition and bivalirudin with or without IIb/IIIa inhibition in patients with acute coronary syndromes: The ACUITY Trial. Presented at the American College of Cardiology Annual Scientific Session: 2006, March 11-14; Atlanta
9. Cohen DJ et al. (2004) Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 44: 1792-1800
10. Nikolsky E et al. (2004) Vascular complications associated with arteriotomy closure devices in patients undergoing percutaneous coronary procedures: A meta-analysis. J Am Coll Cardiol 44: 1200-1209
11. Kiemeneij F et al. (1997) Outpatient coronary stent implantation. J Am Coll Cardiol 29: 323-327